The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO Italy 2022 | The challenges in producing efficacious I-O products for AML
Alessandro Isidori, MD, PhD, Marche Nord Hospital, Pesaro, Italy, discusses the challenges in producing efficacious immuno-oncology (I-O) products for acute myeloid leukemia (AML), emphasizing the heterogeneity and immunosuppressive microenvironment observed in this disease. Dr Isidori explains the genetics of AML, and further evaluates the issue of finding agents that selectively target AML cells while preserving healthy hematopoietic cells. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
